Well, the plot thickens.
Valeant in mid Dec bought the division that has Retin a from J&J for about $400 mill.
The following is based on the assumption that the cosmetics partner is j&j.
Have j&j been formulating a product to compete with this product in their now sold division?
From what I gather it is predominantly a prescription product. Thus doesn't match the mass market formula.
But it doesn't mean a mass market product with TPM is not better than the prescription product. Less active thus not requiring a prescription and better effect even from the lower dose. Remember the prime problem is with irritation.
J&j having their new product fully funded by selling the superceded product and keeping the competition watchdogs happy.
Looks like an elegant business solution.
j & j eats itself
-
- There are more pages in this discussion • 118 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add AVE (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
0.2¢ |
Change
-0.001(33.3%) |
Mkt cap ! $6.338M | |||
| Open | High | Low | Value | Volume |
| 0.2¢ | 0.3¢ | 0.2¢ | $16.54K | 5.758M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 59 | 96791453 | 0.2¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.3¢ | 58594028 | 16 |
View Market Depth
| Last trade - 16.10pm 02/08/2024 (20 minute delay) ? |
| AVE (ASX) Chart |